These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 38824498)
1. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report. Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498 [TBL] [Abstract][Full Text] [Related]
2. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient. Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425 [TBL] [Abstract][Full Text] [Related]
3. [A case of myasthenia gravis and myositis induced by pembrolizumab]. Noda T; Kageyama H; Miura M; Tamura T; Ito H Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124 [TBL] [Abstract][Full Text] [Related]
4. A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma. Newman MT; Bikhchandani M Cancer Rep (Hoboken); 2024 Jul; 7(7):e2140. PubMed ID: 39041627 [TBL] [Abstract][Full Text] [Related]
5. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909 [TBL] [Abstract][Full Text] [Related]
10. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment]. Yao S; Li X; Nong J; Zhang Y Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585 [TBL] [Abstract][Full Text] [Related]
11. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report. Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. Tian CY; Ou YH; Chang SL; Lin CM J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558 [TBL] [Abstract][Full Text] [Related]
13. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report]. Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208 [TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review. Yu H; Wang X; Pan Y; Li H J Neurol; 2024 Aug; 271(8):5326-5332. PubMed ID: 38864881 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced myasthenia gravis: A fatal case report. March KL; Samarin MJ; Sodhi A; Owens RE J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928 [TBL] [Abstract][Full Text] [Related]
18. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis. Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC Front Immunol; 2021; 12():788499. PubMed ID: 34956219 [TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment. Soman B; Dias MC; Rizvi SAJ; Kardos A BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]